Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma

This study aimed to explore the effect of a circular RNA (circRNA), circ_0102049, on OS and reveal its potential molecular mechanism. In this work, the expression of circ_0102049 was detected by quantitative real time polymerase chain reaction (qRT-RCR) in both OS specimens and cell lines. The relationship between circ_0102049 level and patients⿿ overall survival was evaluated by Kaplan-Meier curves and Cox regression analysis. Cell proliferation, apoptosis, migration and invasion of U2OS and MG63 cells were measured by cell counting kit-8 (CCK-8), flow cytometry, wound healing and transwell experiments, respectively. In addition, subcellular fractionation, bioinformatics analysis and dual-luciferase reporter assay were utilized to reveal the mechanism of circ_0102049 in OS. Circ_0102049 was overexpressed in both OS specimens and cells. Moreover, the level of circ_0102049 in OS patients was markedly correlated with larger tumor size, pulmonary metastasis and poor prognosis. Circ_0102049 remarkably accelerated cell proliferation, migration and invasion but attenuated cell apoptosis in OS cells analyzed by gain/loss of function experiments. What⿿s more, we identified that circ_0102049 functions as a competing endogenous RNA (ceRNA) to competitively sponge miR-1304-5p to upregulate MDM2 expression at posttranscriptional level, thus mediating the cellular behaviors of OS cells. Collectively, our study provides an innovatively regulatory mechanism of circ_0102049 in OS and poi...
Source: Pathology Research and Practice - Category: Pathology Source Type: research

Related Links:

Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Cristian Vergallo, Giulia Torrieri, Riccardo Provenzani, Sini Miettinen, Karina Moslova, Markku Varjosalo, Maria Chiara Cristiano, Massimo Fresta, Christian Celia, Hélder A. Santos, Felisa Cilurzo, Luisa Di MarzioAbstractStanozolol (STZ) is a drug used to treat serious disorders like aplastic anemia and hereditary angioedema. It is also indicated as an adjunct therapy for the treatment of vascular disorders and growth failures. Encouraging results obtained using animal models demonstrated that STZ increases bon...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Authors: Šantak G, Frančina M, Gotovac N PMID: 31701810 [PubMed - as supplied by publisher]
Source: Acta Chirurgica Belgica - Category: Surgery Tags: Acta Chir Belg Source Type: research
CONCLUSIONS: The expression of microRNA-330-5p was markedly increased in OS, which was associated with distant metastasis and poor prognosis. Furthermore, we found that microRNA-330-5p may promote the vicious progression of OS by inter-modulating SPRY2 and the TGF-β1/Smad signaling pathways. PMID: 31696462 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: ADPGK-AS1 affected cell proliferation, invasion, migration, and apoptosis via targeting miR-542-3p in OS, providing a theoretical basis and a new therapeutic target for the diagnosis and treatment of OS. PMID: 31696461 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
This study is to produce and utilize novel fully-humanized BERA/miR-328-3p molecule (hBERA/miR-328) to delineate the role of miR-328-3p in controlling nutrient uptake essential for cell metabolism. We first demonstrated successful high-level expression of hBERA/miR-328 in bacteria and purification to high degree of homogeneity (>98%). Biologic miR-328-3p prodrug was selectively processed to miR-328-3p to suppress the growth of highly-proliferative human osteosarcoma (OS) cells. Besides glucose transporter protein type 1, gene symbol solute carrier family 2 member 1 (GLUT1/SLC2A1), we identified and verified large neutra...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Osteosarcoma is the most common primary malignant bone tumor in adults and is usually located in the long bones. Standard treatment consists of perioperative chemotherapy and radical surgical resection. Limb-s...
Source: Journal of Orthopaedic Surgery and Research - Category: Orthopaedics Authors: Tags: Research article Source Type: research
AbstractSoft tissue tumors encompass a wide variety of mesenchymal neoplasms exhibiting diverse clinical, pathologic, and molecular features. Among these, osteoid and/or chondroid matrix deposition in some soft tissue tumors represents a noticeable characteristic. Unlike matrices present in bone tumors where they likely reveal the respective cells of origin (i.e., osteoblastic or chondroblastic precursors), those existing in soft tissue tumors more often denote a metaplastic phenomenon and reflect the diversity of differentiation these tumors can display. While many soft tissue tumor types can occasionally harbor metaplast...
Source: Virchows Archiv - Category: Pathology Source Type: research
Abstract Exosomes secreted by bone marrow mesenchymal stem cells (BMSCs) promote osteosarcoma cell proliferation and migration, while the underlying mechanism remains unknown. Since the long non-coding RNA PVT1 has been reported to be upregulated in osteosarcoma cells and contributes to its growth and metastasis, we aim to investigate whether BMSC-derived exosomes promote osteosarcoma growth and metastasis via transporting PVT1 into osteosarcoma cells. The PVT1 expression in BMSC-derived exosomes was markedly higher than that in osteosarcoma cell-derived exosomes. The co-culturing of BMSC-derived exosomes and oste...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
CONCLUSION: Thus, the circEPSTI1-miR-892b-MCL1 axis affected osteosarcoma progression through miRNA sponging mechanism. circEPSTI1 may serve as a target and biomarker for osteosarcoma treatment. PMID: 31702512 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research
Condition:   Osteosarcoma Interventions:   Drug: Lenvatinib;   Drug: Ifosfamide;   Drug: Etoposide Sponsor:   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Osteosarcoma | Pathology | Study